Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:37:33.107Z.
Calculation as of: 2026-10-06T17:37:33.107Z.
Quote observation: 2026-10-06T17:33:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2100d4567e155cb65401b1d64ef1112e8effddeb5d941ccec26242c7dbad22d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Orchestra BioMed Holdings, Inc.
Market Cap
$353.00M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.34M
Price/FCF Ratio
N/A
TTM Avg
54.19
3Y Avg
39.66
5Y Avg
37.45
Market Cap
$353.80M
Price/FCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
Market Cap
$353.91M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$348.35M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $353.00M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.34M | N/A | 54.19 | 39.66 | 37.45 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $353.80M | N/A | 6.69 | 6.69 | 6.69 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $353.91M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $355.07M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $356.88M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.35M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $359.17M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $360.42M | 2.19 | 2.83 | 26.37 | 19.21 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $374.62M | N/A | 25.86 | 25.37 | 25.37 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
